Methoxsalen


Generic Medicine Info
Administration
Should be taken with food.
Contraindications
Aphakia, existing or history of melanoma, invasive squamous cell carcinoma, photosensitivity diseases (e.g. porphyria, acute lupus erythematosus, xeroderma pigmentosum).
Special Precautions
Patient exhibiting multiple basal cell carcinoma or history of basal cell carcinoma, previous arsenic therapy, previous x-ray or grenz ray therapy; cardiac diseases or those unable to tolerate prolonged standing or exposure to heat stress; GI diseases or chronic infection. Hepatic impairment. Pregnancy and lactation. Patient Counselling Keep the treated areas protected from light by use of protective clothing or sunscreen. Monitoring Parameters Conduct CBC w/ differential; liver and renal function, antinuclear antibody tests (at baseline and 6-12 mthly); ophth exam (pre-treatment and yrly); signs/symptoms of skin cancer, burns, photosensitivity.
Adverse Reactions
Oral: Nausea, insomnia, nervousness, depression. Photochemotherapy or PUVA: Mild transient erythema, pruritus; dizziness, headache, oedema, vesiculation, acneform eruption, bulla formation, severe skin pain, altered skin or nail pigmentation, onycholysis, premature skin ageing, severe burns, hypertrichosis.
Potentially Fatal: Increased risk of malignant cutaneous neoplasms.
Drug Interactions
May increase plasma concentration of drugs metabolised by CYP2A6 isoenzyme. Additive effect w/ other systemic or topical photosensitising agents (e.g. anthralin, coal tar, nalidixic acid).
ATC Classification
D05AD02 - methoxsalen ; Belongs to the class of topical psoralens used in the treatment of psoriasis.
D05BA02 - methoxsalen ; Belongs to the class of systemic psoralens used in the treatment of psoriasis.
Disclaimer: This information is independently developed by CIMS based on methoxsalen from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in